Abstract Body

Background

Chronic inflammation and immune dysfunction persist in some people with HIV (PWH), even during antiretroviral therapy (ART). We previously observed that HIV-1 soluble gp120 (sgp120) and a family of gp120-specific anti-cluster A antibodies (Abs) are associated with chronic inflammation and immune dysfunction in aviremic participants of the Canadian HIV and Aging cohort. Here, we evaluated whether antibodies targeting the CD4 binding site of gp120 (CD4BS) could prevent CD4 depletion in vitro, and how their presence in the plasma of PWH could affect the negative association between anti-cluster A Abs and CD4 cell counts.

Methods

We first evaluated the capacity of CD4BS Abs or plasma from PWH to prevent CD4 depletion in vitro. We next performed a cross-sectional assessment of anti-cluster A Abs and anti-CD4BS Abs in three independent cohorts of PWH. We used generalized least squares linear regression models with random effects (considering clustering within cohorts) to estimate the association between anti-cluster A Abs and CD4 counts. Next, we assessed how this association was affected by the presence or the absence of anti-CD4BS Abs by adding an interaction term to the model.

Results

In vitro, we observed that CD4BS Abs blocked the coating of uninfected bystander CD4+ T cell by sgp120 and their elimination by ADCC mediated by plasma from PWH (p<0.0001). Plasma from participants with anti-CD4BS Abs also decreased the coating of CD4+ T cells with sgp120 (p=0.0089) and prevented their ADCC-mediated elimination (p=0.0001). We included 520 participants from three independent cohorts for measurements of anti-cluster A Abs and anti-CD4BS Abs. The mean age of participants was 56, 87% were males, and the median duration of HIV infection was 20.7 years. ~16% of PWH (82/520) had detectable levels of anti-CD4BS Abs. In the total study population, anti-cluster A Abs were inversely associated with CD4 cell counts (beta; -18.32 95%CI -32.85 to -3.79, p=0.013). The strength of this association was increased in those without anti-CD4bs Abs (beta; -26.74 95%CI -42.52 to -10.96, p=0.001). This association was not present in PWH with anti-CD4BS Abs (beta; 19.77 95%CI -19.42 to 58.95, p-value for interaction 0.02).

Conclusions

Our results suggest that sgp120-mediated immune dysfunction is associated with its capacity to interact with CD4, and that anti-CD4BS Abs negate this capacity, which could lead to novel therapeutic approaches to tackle residual immune dysfunction in PWH.

Table or Figure